[artículo] 
inJournal of Clinical Psychopharmacology > Año 2011 - Vol. 31 - No. 5 (Octubre) . - PP. 603-612

Título :	Antagonist elicited cannabis withdrawal in humans
Tipo de documento:	texto impreso
Autores:	David A Gorelick, Autor ; Robert S. Goodwin, Autor ; Eugene Schwilke, Autor
Fecha de publicación:	2022
Artículo en la página:	PP. 603-612
Idioma :	Inglés (eng) Idioma original : Inglés (eng)
Palabras clave:	Antagonista, Cannabis, Marihuana, Rimonabant, Abstinencia
Resumen:	Cannabinoid CB1 receptor antagonists have potential therapeutic benefits, but antagonist-elicited cannabis withdrawal has not been reported in humans. Ten male daily cannabis smokers received 8 days of increasingly frequent 20-mg oral Δ9-tetrahydrocannabinol (THC) dosages (40-120 mg/d) around-the-clock to standardize cannabis dependence while residing on a closed research unit.
Link:	./index.php?lvl=notice_display&id=29356

[artículo] Antagonist elicited cannabis withdrawal in humans [texto impreso] / David A Gorelick, Autor ; Robert S. Goodwin, Autor ; Eugene Schwilke, Autor . - 2022 . - PP. 603-612.
Idioma : Inglés (eng) Idioma original : Inglés (eng)
in Journal of Clinical Psychopharmacology > Año 2011 - Vol. 31 - No. 5 (Octubre) . - PP. 603-612

Palabras clave:	Antagonista, Cannabis, Marihuana, Rimonabant, Abstinencia
Resumen:	Cannabinoid CB1 receptor antagonists have potential therapeutic benefits, but antagonist-elicited cannabis withdrawal has not been reported in humans. Ten male daily cannabis smokers received 8 days of increasingly frequent 20-mg oral Δ9-tetrahydrocannabinol (THC) dosages (40-120 mg/d) around-the-clock to standardize cannabis dependence while residing on a closed research unit.
Link:	./index.php?lvl=notice_display&id=29356